Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Cronus Ink Distribution Deal for UK, Ireland

NEW YORK (GenomeWeb News) – Cronus Technologies and Axela today announced a distribution deal to market Axela's instruments in the UK and Ireland.

Cronus will manage the sales and support of Axela's flow-through systems in both countries under the terms of the deal. The systems include the fully automated Ziplex Research System for gene and protein microarray analysis, and the dotLab mX System for real-time, multiplex immunoassays. Cronus will also market Axela's panelPlus Technology for creating custom multiplex panels for flow-through biomarker analysis.

"The Ziplex and dotLab mX product range adds another string to our biomarker discovery and validation portfolio and allows us to truly collaborate with our customers in a meaningful and strategic way," Kevin Fairman, CEO of Cronus, said in a statement. "This positive addition combined with a great working relationship with the Axela team will allow our customers to push the boundaries and time constraints in biomarker research."

The companies did not reveal the terms of the deal, which follows an agreement Toronto-based Axela inked with Digilab in August to distribute Axela's products in the US.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.